Annexon, Inc.
ANNX
NASDAQ
Last Updated: 6/9/2023 8:00:04 PM
High
Low
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.Annexon, Inc. Company Details
CEO: Mr. Douglas Love Esq., J.D.
Country: US
Industry: Biotechnology
Website: https://www.annexonbio.com
Exchange: NASDAQ Global Select
IPO\Launch Date: 2020-07-24
Annexon, Inc. Company Executive Details
Dr. Dean R. Artis Ph.D.
Chief Scientific Officer
Henk-Andre Kroon M.D.
Senior Vice President of Translational Medicine
Dr. Ted Yednock Ph.D.
Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
Mr. Douglas Love J.D., Esq.
Chief Executive Officer, Pres & Director
Mirella Villa Del Toro
Sec.
Annexon, Inc. Latest News
Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.
Published on: 2023-05-30 11:55:06
Impact on Symbol / Company: ANNX
View News
Why Shares of Annexon Are Plummeting Thursday
Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (GA) was approved by the FDA in February.
Published on: 2023-05-25 11:52:31
Impact on Symbol / Company: ANNX
View News
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%, EHTH +13.2%, FLNC +9%, ALLK +7.5%. The Active ETF portfolio continues with YTD gains at +10.6%.
Published on: 2023-05-21 09:23:18
Impact on Symbol / Company: ANNX
View News
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but peak gains were in COIN +14.4% and TLRY +7.1%. The Active ETF portfolio continues with YTD gains at +14.2%.
Published on: 2023-05-14 07:47:41
Impact on Symbol / Company: ANNX
View News
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge.
Published on: 2023-04-23 08:01:40
Impact on Symbol / Company: ANNX
View News
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT in San Francisco.
Published on: 2023-01-04 06:30:00
Impact on Symbol / Company: ANNX
View News
Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues
Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain. The 28 patients were dosed for six months and followed for three more.
Published on: 2022-06-07 12:29:05
Impact on Symbol / Company: ANNX
View News
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.
Published on: 2022-06-02 06:30:00
Impact on Symbol / Company: ANNX
View News
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the company will present data from across its complement-targeted pipeline at several upcoming medical meetings.
Published on: 2022-06-01 07:30:00
Impact on Symbol / Company: ANNX
View News
Annexon Biosciences to Participate in Upcoming May Investor Conferences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:
Published on: 2022-05-05 06:30:00
Impact on Symbol / Company: ANNX
View News
What Are Penny Stocks? What You Need to Know and 3 to Watch
Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Published on: 2022-04-20 15:41:34
Impact on Symbol / Company: ANNX
View News
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington's Disease at AAN 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that the company will present preclinical data highlighting its approach of inhibiting C1q to address a number of complement-mediated diseases. The data are being presented in oral and poster sessions at the American Academy of Neurology (AAN) Annual meeting, being held in Seattle from April 2-7, 2022, and virtually from April 24-26, 2022.
Published on: 2022-03-03 16:01:00
Impact on Symbol / Company: ANNX
View News
Grow your Money
We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures
Services we Offer
We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others
Live Market Data
We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you